- Reference code :
- wf444
- Published date :
-
06 August 2002
- Expired date :
-
22 December 2029
Following a constructive meeting with the US Food and Drug Administration (FDA) to discuss the company's response to the approvable letter for Crestor (rosuvastatin calcium), AstraZeneca has undertaken to provide further information from its ongoing study programme to supplement that already submitted.
This response to the approvable letter will support the use of Crestor over the dose range of 10-40mg in the general population of patients with lipid disorders and is scheduled for submission during the first quarter 2003.
There are now more than 10,000 patients in on-going studies of Crestor and the company remains confident in the product's profile and commercial potential.
The company's guidance on earnings for 2002 remains unchanged.
Further enquires to:
Media EnquiriesChris Major +44 (0)20 7304 5028 Steve Brown +44 (0)20 7304 5033 |
Investor RelationsMina Blair-Robinson +44 (0)20 7304 5084 Jonathan Hunt +44 (0)20 7304 5087 Jorgen Winroth +1 212 581 8720 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
